SCHEMBL2927353

SCHEMBL2927353

CC(C)(C)OC(=O)N1CCN(CCCn2cc3c(-c4ccc(F)cc4)c(-c4ccncc4)c(-c4ccc(F)cc4)nc3n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 1/20 0.42
GRIA1 P42261 1/20 0.42
ACKR3 P25106 3/20 0.41
HRH2 P25021 1/20 0.40
HRH1 P35367 1/20 0.40
MAPK14 Q16539 5/20 0.40
PLK1 P53350 1/20 0.39
F2RL1 P55085 2/20 0.38
GPR119 Q8TDV5 2/20 0.37
MAPK11 Q15759 3/20 0.37
MAPK13 O15264 2/20 0.37
MAPK12 P53778 2/20 0.37
KDM1A O60341 1/20 0.36
KCNH2 Q12809 1/20 0.36
CSNK1D P48730 1/20 0.36
CSNK1E P49674 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2927906 0.95 SQOR (0.43) SQORGRIA1ACKR3HRH2HRH1
SCHEMBL2931587 0.87 GPR119 (0.43) GRIA1MAPK14GPR119MAPK11KCNH2
SCHEMBL2926317 0.86 NPY5R (0.40) MAPK14MAPK11KCNH2CSNK1DCSNK1E
SCHEMBL2931749 0.85 GPR119 (0.43) GRIA1MAPK14GPR119MAPK11KCNH2
SCHEMBL2925845 0.84 GPR119 (0.41) GRIA1MAPK14GPR119MAPK11KCNH2
SCHEMBL2925785 0.84 NAMPT (0.41) GRIA1MAPK14GPR119MAPK11KCNH2
SCHEMBL1386122 0.83 MAPK14 (0.48) GRIA1MAPK14MAPK11MAPK13MAPK12
SCHEMBL1384906 0.82 MAPK14 (0.42) MAPK14MAPK11MAPK13MAPK12CSNK1D
SCHEMBL2934053 0.81 SQOR (0.49) SQORGRIA1ACKR3HRH2HRH1
SCHEMBL2926287 0.81 NPY5R (0.41) MAPK14MAPK11KCNH2CSNK1DCSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 SQOR 823/4885GRIA1 2222/4885ACKR3 1919/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 SQOR 753/4885GRIA1 1663/4885ACKR3 1601/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 SQOR 753/4885GRIA1 1663/4885ACKR3 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.